Amisulpride is a neuroleptic. Amisulpride binds selectively with a high affinity to human dopaminergic D2/D3 receptor subtypes whereas it is devoid of affinity for D1, D4 and D5 receptor subtypes.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Amisulpride is the active ingredient of these drugs:
Cyprus Lithuania Netherlands
Australia Austria Cyprus France Germany
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):